NCT05138575View on ClinicalTrials.gov

SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2026

Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
DRUG

Empagliflozin + Potassium Chloride

"Empagliflozin is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle.~KCl is an active control."

DRUG

Empagliflozin + Potassium Nitrate

Empagliflozin + KNO3 is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle, as well as increase skeletal muscle perfusion during exercise.

DRUG

Potassium Chloride + Placebo for Empagliflozin

Active control.

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania Health System, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER